Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT04221945 - Cisplatin + Pembrolizumab + Radiation / Radiotherapy (RT) vs Cisplatin + Radiation / Radiotherapy (RT) & Cervical cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

Primary outcome measure:
Progression-Free Survival (PFS), Overall Survival (OS)

On January 12, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on this trial.

…

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

NCT04221945 - Cisplatin + Pembrolizumab + Radiation / Radiotherapy (RT) vs Cisplatin + Radiation / Radiotherapy (RT) & Cervical cancer

Welcome to meRfi Microbiome!

Navigation

Contents

AI Chat

Links